Elutia Inc. (ELUT): EBITDA
-$24.13M
Year ended 2025-12-31
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$24.13M | n/m | 2026-03-13, From 2025-01-01 |
| 2024-12-31 | -$27.26M | n/c | 2026-03-13, From 2024-01-01 |
| 2023-12-31 | -$26.78M | n/m | 2025-03-11, From 2023-01-01 |
| 2022-12-31 | -$31.46M | n/c | 2024-03-11, From 2022-01-01 |
| 2021-12-31 | -$19.30M | n/m | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | -$9.73M | n/m | 2022-03-08, From 2020-01-01 |
| 2019-12-31 | -$4.55M | n/a | 2021-03-15, From 2019-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Elutia Inc. (ELUT) | 2025-12-31 | -$24.13M | n/m |
| Passage BIO, Inc. (PASG) | 2025-12-31 | -$48.57M | n/m |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | -$48.60M | n/m |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | -$117.28M | n/m |
| Armata Pharmaceuticals, Inc. (ARMP) | 2024-12-31 | -$41.11M | n/m |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | -$22.60M | n/m |
| Cognition Therapeutics Inc (CGTX) | 2025-12-31 | -$47.76M | n/m |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | -$76.96M | n/m |
| Quince Therapeutics, Inc. (QNCX) | 2025-12-31 | -$57.93M | n/m |
Compare ELUT, PASG, CRDF, SGMOQ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗